On November 30,2022 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") reported that three posters showcasing IPH5201 and IPH5301 will be presented on December 8 at the 2022 European Society for Medical Oncology I-O (ESMO Immuno-Oncology) Annual Congress in Geneva, Switzerland (Press release, Innate Pharma, NOV 30, 2022, View Source [SID1234624626]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The following posters will be presented:
IPH5201 as monotherapy or in combination with durvalumab in advanced solid tumors (AstraZeneca)
Abstract Number: 472
Session Name: Poster Display 188P
Session Time: 8 December, 12:30-13:15
Location: Palexpo exhibition centre – Foyer ABC
Presenter: Dr. Martina Imbimbo, Head of Clinic for the Immuno-oncology Department within the Department of Oncology at UNIL CHUV (Lausanne, Switzerland)
Combination of IPH5201, a block antibody targeting the CD39 immunosuppressive pathway, with durvalumab and chemotherapies: Preclinical rationale
Abstract Number: 384
Session Name: Poster Display 190P
Session Time: 8 December, 12:30-13:15
Location: Palexpo exhibition centre – Foyer ABC
Presenter: Carine Paturel, Senior Director, Research and Drug Development, Products Portfolio Strategy, Innate Pharma (Marseille, France)
A first-in-human phase I study of IPH5301, an anti-CD73 monoclonal antibody, alone or in combination with chemotherapy and trastuzumab, in patients with advanced solid tumors (CHANCES) (Institut Paoli-Calmettes)
Abstract Number: 290
Session Name: Poster Display 199TiP
Session Time: 8 December, 12:30-13:15
Location: Palexpo exhibition centre – Foyer ABC
Presenter: Dr. Anthony Gonçalves, Professor of Medical Oncology, Institut Paoli-Calmettes (Marseille, France)
The posters will be available on the Publications section of Innate’s website following the meeting.
About IPH5201
IPH5201 is a CD39-blocking monoclonal antibody that may promote antitumor immunity by increasing immunostimulatory ATP and reducing immunosuppressive adenosine levels in the tumor microenvironment. It is being developed in partnership with AstraZeneca.
A first-in-human, multi-centre, non-randomised, open-label, phase 1 study (NCT04261075) sponsored by AstraZeneca assessed the safety, efficacy, pharmacokinetics and pharmacodynamics of IPH5201 as monotherapy and in combination with durvalumab in patients with advanced solid tumors.
A Phase 2 clinical trial conducted by Innate in lung cancer is in planning.
About IPH5301
IPH5301 is a CD73-blocking monoclonal antibody currently in an investigator-sponsored Phase 1 trial in collaboration with the Institut Paoli-Calmettes (IPC) and Oncodistinct Network.
By targeting the adenosine immunosuppressive pathway, IPH5301 has the potential to promote anti-tumor immune responses across a wide range of tumors.